Please Wait
Applying Filters...
menu
    • menu
    FDA’s landmark approvals of BMS’ schizo med, Madrigal’s MASH drug, US$ 16.5 bn Catalent buyout make it to top 10 news of 2024

    Data Compilation
    #PharmaFlow

    Pipeline Prospector 2024 highlights: Rise in new breed of biotechs with maiden approvals; GLP-1 meds show promise beyond obesity

    Stock Recap
    #PipelineProspector

    Menu

    Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 259,892Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name Registration No. Compound Registration Date Manufacturer Manufacturer's Country Manufacturer's Address
    30/12/2024 Yonsung Fine Chemicals
    South Korea
    		 YS Life Science Co., Ltd. 20241230-211-J-1736 Cabergoline 2024-12-30 YS Life Science Co., Ltd. South Korea 207 Sujeong-ro, Jangan-myeon, Hwaseong-si, Gyeonggi-do